Trial Profile
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jan 2017
Price :
$35
*
At a glance
- Drugs Catridecacog (Primary)
- Indications Factor XIII deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 19 May 2015 New trial record